RxDoctor Payments Data

Huan Huynh, MD

Epilepsy · Weston, FLNPI 1801280268

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,400 of the $3,371 with a category attached, or 71.2%. 10 manufacturers reported payments, led by Livanova USA, Inc. at 52.4% of the total. Reporting peaked in 2023 at $2,170 and has fallen 63.7% since, to $787 in 2025. That places this record below the midpoint for epilepsy clinicians in FL, where the typical reported total is $6,512.

$3,371in general payments, 2019–2025

Across 20 payments — averaging $168.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • DIXI Medical USA Corp$981
  • Medtronic$202
  • Catalyst Pharmaceuticals, Inc.$141
  • Monteris Medical Corporation$118
  • UCB, Inc.$58
  • plus $105 from 4 others

What the payments were for

  • Consulting fees$40012%
  • Travel & lodging$55416%
  • Food & beverage$2,40071%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,371 in reported general payments places this provider in the 35th percentile of 23 epilepsy providers in Florida.

See all epilepsy providers in Florida

Medicare billing

Part B allowed, 2024
$58,159
Medicare patients
120
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate19$40,187
BriviactBrivaracetam21$36,422
Diazepam18$4,689
Lacosamide43$2,399
Oxcarbazepine25$1,675
Levetiracetam26$1,440
Phenobarbital20$1,182
Clobazam15$957
Phenytoin Sodium Extended14$585
Zonisamide14$309
Clonazepam13$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$58$36,42221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 23 epilepsy providers in Florida.

Other epilepsy in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →